Log In
BCIQ
Print this Print this
 

Aerosurf, lucinactant

  Manage Alerts
Collapse Summary General Information
Company Windtree Therapeutics Inc.
DescriptionAerosolized KL4 surfactant
Molecular Target
Mechanism of Action 
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentPhase II
Standard IndicationRespiratory distress syndrome (RDS)
Indication DetailsPrevent respiratory distress syndrome (RDS) in premature infants; Treat respiratory distress syndrome (RDS); Treat respiratory distress syndrome (RDS) in premature infants
Regulatory Designation U.S. - Fast Track (Treat respiratory distress syndrome (RDS) in premature infants)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$7.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/15/2014

Undisclosed

0

$7.5M

Get a free BioCentury trial today